Sun Pharma Shares Analyzed
Sun Pharma’s stock price dropped significantly on Thursday, falling by over 2%. This happened after the US Food and Drug Administration (FDA) found some issues during an inspection of one of the company’s factories. Investors reacted negatively to this news, causing the stock to fall to ₹1,746.1 per share.
Key Points
- FDA inspection revealed problems at a Sun Pharma factory.
- Stock price decreased by over 2% due to the findings.
- Shares hit a low since November 2024 currently.
- Company continues supplying products to the US market.
- Revenue grew 8.93% in Q2FY26, driven by global growth.
- Long-term growth fueled by India and specialty medicines.
The FDA started its inspection on September 8, 2025, and finished on September 19, 2025. They labeled the inspection as “Official Action Indicated (OAI),” which is a serious warning. Sun Pharma says it’s still making and selling medicines to the US, and they’re working closely with the FDA to fix everything.
Sun Pharma’s financial results show a positive trend. The company’s revenue increased by 8.93% to ₹14,478 crore in the second quarter of the financial year 2026. Their profit also grew by 2.56% compared to the previous year. This growth came from sales in India, other emerging markets, and around the world.
However, the US market didn’t perform as well, with revenue dropping by 4.1%. Financial analysts have also raised concerns. Nirmal Bang suggests that higher taxes and competition will put pressure on earnings. Motilal Oswal has lowered their forecasts due to increased spending on new medicines and higher taxes.
Despite these challenges, Sun Pharma has strong long-term growth opportunities. They are doing well in India, developing new medicines like LEQSELVI and UNLOXCYT, and are looking to expand into dermatology, eye care, and cancer treatment. Their financial strength will help them continue to grow even with these changes.
Sun Pharma’s future success depends on successfully addressing FDA concerns and continuing to invest in innovative medicines and expanding into new markets.
